Literature DB >> 12101389

Modulation of apoptosis by HIV protease inhibitors.

B N Phenix1, C Cooper, C Owen, A D Badley.   

Abstract

Advances in treatment have transformed the Human Immunodeficiency Virus (HIV) infection from a progressive and ultimately fatal disease to one that can be managed effectively by chronic suppressive antiretroviral therapy. The drugs now used to treat HIV infection not only inhibit viral replication but also have effects on cellular metabolism and homeostasis. Of particular interest to cellular immunologists, members of the HIV Protease Inhibitor (PI) class of antiretroviral agents possess intrinsic immunomodulatory and antiapoptotic properties. This review focuses on the development and use of PI together with their impact on HIV disease, immunity, and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12101389     DOI: 10.1023/a:1016168411221

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  6 in total

1.  Short communication: enhanced CD8+ T cell apoptosis in HIV-infected adolescents with virologic failure on protease inhibitor-based therapy.

Authors:  Jun Zuo; Joseph Church; Marvin Belzer; Christina Kitchen; Bonnie Ank; Ingrid Schmid; Paul Krogstad
Journal:  AIDS Res Hum Retroviruses       Date:  2010-06       Impact factor: 2.205

2.  Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.

Authors:  Joel G R Weaver; Agathe Tarze; Tia C Moffat; Morgane Lebras; Aurelien Deniaud; Catherine Brenner; Gary D Bren; Mario Y Morin; Barbara N Phenix; Li Dong; Susan X Jiang; Valerie L Sim; Bogdan Zurakowski; Jessica Lallier; Heather Hardin; Peter Wettstein; Rolf P G van Heeswijk; Andre Douen; Romano T Kroemer; Sheng T Hou; Steffany A L Bennett; David H Lynch; Guido Kroemer; Andrew D Badley
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

Review 3.  How I treat HIV-associated lymphoma.

Authors:  Kieron Dunleavy; Wyndham H Wilson
Journal:  Blood       Date:  2012-02-15       Impact factor: 22.113

4.  HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice.

Authors:  Toshio Hisatomi; Toru Nakazawa; Kousuke Noda; Lama Almulki; Shinsuke Miyahara; Shintaro Nakao; Yasuhiro Ito; Haicheng She; Riichiro Kohno; Norman Michaud; Tatsuro Ishibashi; Ali Hafezi-Moghadam; Andrew D Badley; Guido Kroemer; Joan W Miller
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

5.  Association of early HIV viremia with mortality after HIV-associated lymphoma.

Authors:  Satish Gopal; Monita R Patel; Elizabeth L Yanik; Stephen R Cole; Chad J Achenbach; Sonia Napravnik; Greer A Burkholder; Erin G Reid; Benigno Rodriguez; Steven G Deeks; Kenneth H Mayer; Richard D Moore; Mari M Kitahata; Kristy L Richards; Joseph J Eron
Journal:  AIDS       Date:  2013-09-24       Impact factor: 4.177

6.  Luminescent PLGA Nanoparticles for Delivery of Darunavir to the Brain and Inhibition of Matrix Metalloproteinase-9, a Relevant Therapeutic Target of HIV-Associated Neurological Disorders.

Authors:  Tiziana Latronico; Federica Rizzi; Annamaria Panniello; Valentino Laquintana; Ilaria Arduino; Nunzio Denora; Elisabetta Fanizza; Serafina Milella; Claudio M Mastroianni; Marinella Striccoli; Maria Lucia Curri; Grazia M Liuzzi; Nicoletta Depalo
Journal:  ACS Chem Neurosci       Date:  2021-11-02       Impact factor: 5.780

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.